SG11202009874QA - Antibody formulation - Google Patents

Antibody formulation

Info

Publication number
SG11202009874QA
SG11202009874QA SG11202009874QA SG11202009874QA SG11202009874QA SG 11202009874Q A SG11202009874Q A SG 11202009874QA SG 11202009874Q A SG11202009874Q A SG 11202009874QA SG 11202009874Q A SG11202009874Q A SG 11202009874QA SG 11202009874Q A SG11202009874Q A SG 11202009874QA
Authority
SG
Singapore
Prior art keywords
antibody formulation
antibody
formulation
Prior art date
Application number
SG11202009874QA
Other languages
English (en)
Inventor
Murali Jayaraman
Anuja Chandrasekar
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of SG11202009874QA publication Critical patent/SG11202009874QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202009874QA 2018-04-10 2019-04-10 Antibody formulation SG11202009874QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841013646 2018-04-10
PCT/IN2019/050292 WO2019198100A1 (en) 2018-04-10 2019-04-10 Antibody formulation

Publications (1)

Publication Number Publication Date
SG11202009874QA true SG11202009874QA (en) 2020-11-27

Family

ID=68163986

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202009874QA SG11202009874QA (en) 2018-04-10 2019-04-10 Antibody formulation

Country Status (10)

Country Link
US (1) US12030948B2 (enrdf_load_stackoverflow)
EP (1) EP3773694A4 (enrdf_load_stackoverflow)
JP (2) JP2021521159A (enrdf_load_stackoverflow)
CN (1) CN112218654A (enrdf_load_stackoverflow)
AU (1) AU2019253070A1 (enrdf_load_stackoverflow)
BR (1) BR112020020707A2 (enrdf_load_stackoverflow)
CO (1) CO2020013552A2 (enrdf_load_stackoverflow)
SG (1) SG11202009874QA (enrdf_load_stackoverflow)
WO (1) WO2019198100A1 (enrdf_load_stackoverflow)
ZA (1) ZA202006263B (enrdf_load_stackoverflow)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773695A4 (en) * 2018-04-10 2021-12-22 Dr. Reddy's Laboratories Ltd. STABLE ANTIBODY FORMULATION
IL297841A (en) * 2020-05-11 2023-01-01 Medimmune Ltd Formulations of anti-il-33 antibodies
WO2024098180A1 (en) * 2022-11-07 2024-05-16 Wuxi Biologics (Hong Kong) Limited Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same
WO2022101935A1 (en) * 2020-11-12 2022-05-19 Dr. Reddy’S Laboratories Limited Stable aqueous high concentration formulation of integrin antibody
WO2022157806A1 (en) * 2021-01-20 2022-07-28 Dr. Reddy's Laboratories Limited Freeze dried antibody formulations and methods thereof
AU2022271025A1 (en) * 2021-05-07 2023-12-14 Dr. Reddy’S Laboratories Limited A method of improving stability of an antibody formulation
WO2022253994A1 (en) * 2021-06-04 2022-12-08 Polpharma Biologics S.A. Vedolizumab formulation
CN113813377A (zh) * 2021-09-07 2021-12-21 杭州远大生物制药有限公司 抗α4β7抗体制剂及其应用
WO2024102675A1 (en) 2022-11-07 2024-05-16 Upstream Bio, Inc. Pharmaceutical compositions comprising anti-human tslp receptor antibodies and methods of using the same
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
WO2025041000A1 (en) * 2023-08-21 2025-02-27 Intas Pharmaceuticals Ltd. STABLE LIQUID CITRATE FREE FORMULATION OF AN ANTI-α4β7 ANTIBODY

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2236154T1 (en) * 2003-02-10 2018-08-31 Biogen Ma Inc. THE FORM OF IMUNOGLOBULIN AND THE METHOD OF ITS PREPARATION
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
WO2012076670A2 (en) * 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EP2704742B1 (en) * 2011-05-02 2017-07-12 Millennium Pharmaceuticals, Inc. Formulation for anti- 4 7 antibody
WO2017015198A1 (en) * 2015-07-17 2017-01-26 Coherus Biosciences, Inc. Stable aqeous formulations of natalizumab
WO2019147824A1 (en) * 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
WO2020104705A2 (en) * 2018-11-23 2020-05-28 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease

Also Published As

Publication number Publication date
EP3773694A1 (en) 2021-02-17
EP3773694A4 (en) 2021-12-29
JP2024001364A (ja) 2024-01-09
CN112218654A (zh) 2021-01-12
US20210147555A1 (en) 2021-05-20
JP2021521159A (ja) 2021-08-26
ZA202006263B (en) 2022-01-26
US12030948B2 (en) 2024-07-09
AU2019253070A2 (en) 2020-12-03
CO2020013552A2 (es) 2021-01-18
WO2019198100A1 (en) 2019-10-17
BR112020020707A2 (pt) 2021-01-12
AU2019253070A1 (en) 2020-11-26

Similar Documents

Publication Publication Date Title
IL279321A (en) Anti-SIRPalpha antibody
IL269499A (en) Stable antibody formulation
ZA202006263B (en) Antibody formulation
GB201817172D0 (en) Antibody
IL281255A (en) CSF-1R antibody formulation
IL271416A (en) Bispecific antibody formulation
IL282813A (en) Formulation of antibodies
IL281717B2 (en) Antibody formulation
ZA202101177B (en) Anti-btla antibody
GB201801614D0 (en) Formulation
SG11202102875YA (en) Anti-fgfr2 antibody formulations
GB201811368D0 (en) Antibody
GB201817867D0 (en) Aerosolisable formulation
IL282567A (en) Aerosol formulation
IL282523A (en) Aerosol formulation
GB201816447D0 (en) Formulation
SG11202104012QA (en) Antibody formulations
GB201817859D0 (en) Aerosolisable formulation
IL282461A (en) Aerosol formulation
GB201817863D0 (en) Aerosolisable formulation
GB201817864D0 (en) Aerosolisable formulation
GB201813229D0 (en) Formulation
GB201811926D0 (en) Aerosolisable formulation
GB201807312D0 (en) Formulation
ZA202006262B (en) Stable antibody formulation